HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of roux-en Y gastric bypass surgery on prognostic factors of type 2 diabetes mellitus: meta-analysis and systematic review.

Abstract
Our aim is to clarify the features of complete type 2 diabetes mellitus (T2DM) remission in patients who undergo Roux-en Y gastric bypass surgery, to better determine factors affecting the outcome of T2DM surgery. A search was conducted for original studies on Medline, PubMed and Elsevier from inception until October 28, 2014. All of the articles included in this study were assessed with the application of predetermined selection criteria and were divided into two groups: Roux-en Y gastric bypass surgery for T2DM patients in remission or non-remission. The meta-analysis results demonstrated that fasting C-peptide values were significantly associated with increased remission (C-peptide: 95%CI = 0.2-1.0) whereas T2DM duration, patient age, preoperative insulin use, preoperative fasting blood glucose values and preoperative glycosylated haemoglobin values were significantly associated with reduced remission (T2DM duration: 95%CI = -1.2 - -0.7; age: 95%CI = -0.5 - -0.1; percentage of preoperative insulin users: odd ratio = 0.10, 95%CI = 0.07-0.15; preoperative fasting blood glucose: 95%CI = -0.9 - -0.5; preoperative glycosylated haemoglobin: 95%CI = -1.1 - -0.4). However, the results demonstrated that body mass index was not statistically different (body mass index: 95%CI = -0.2-0.6). The results of the systematic review demonstrated that smaller waist circumference; lower total cholesterol, triglycerides and low-density lipoprotein levels, increased higher high-density lipoprotein levels, shorter cardiovascular disease history and less preoperative prevalence of hypertension contribute to the increased postoperative remission rate. Better results are obtained in younger patients with less severe diabetes, a smaller waist circumference, higher preoperative high-density lipoprotein, lower preoperative total cholesterol, triglycerides and low-density lipoprotein levels and fewer other complications of shorter durations.
AuthorsYali Chen, Guangzheng Zeng, Jingwang Tan, Jun Tang, Jingsheng Ma, Benqiang Rao
JournalDiabetes/metabolism research and reviews (Diabetes Metab Res Rev) Vol. 31 Issue 7 Pg. 653-62 (Oct 2015) ISSN: 1520-7560 [Electronic] England
PMID25387821 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
CopyrightCopyright © 2014 John Wiley & Sons, Ltd.
Chemical References
  • Blood Glucose
  • C-Peptide
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Triglycerides
  • hemoglobin A1c protein, human
  • Cholesterol
Topics
  • Age Factors
  • Blood Glucose (metabolism)
  • Body Mass Index
  • C-Peptide (metabolism)
  • Cholesterol (metabolism)
  • Diabetes Mellitus, Type 2 (complications, drug therapy, metabolism)
  • Gastric Bypass
  • Glycated Hemoglobin (metabolism)
  • Humans
  • Hypertension (complications)
  • Hypoglycemic Agents (therapeutic use)
  • Insulin (therapeutic use)
  • Lipoproteins, HDL (metabolism)
  • Lipoproteins, LDL (metabolism)
  • Obesity, Morbid (complications, surgery)
  • Prognosis
  • Remission Induction
  • Treatment Outcome
  • Triglycerides (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: